Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Emergent BioSolutions Inc.NYSE: EBS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 43.3%

Gross margin was 43.3% in Q1 FY2026, down 9.1 pp from a year earlier. On a trailing-twelve-month basis it was 44.4%, up 8.0 pp year over year. Over 3 fiscal years it widened by 4.9 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
43.3%+12.0 pp QoQ
Last fiscal yearDec 2025
47.2%+11.2 pp YoY
LTMMar 2026
44.4%+8.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-9.1 pp——
1 year+11.2 pp——
3 years+4.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
47.2%
Year-over-year change
+11.2pp

Gross Margin vs competitors

How EBS compares with its peers on the latest reported figures

  • EBS's LTM Mar 2026 gross margin of 44.4% is the 7th highest of the 8 companies compared; the peer median is 65.0%.
  • Its year-over-year change of +8.0 pp is the highest of 8, against a peer median of -4.9 pp.
  • Over three fiscal years its change of +4.9 pp compares with a peer median of -1.1 pp.
EBS Competitors Peer median
Gross Margin for EBS and competitors
Company Period LTM level YoY 3-year change
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 202670.4% -5.4 pp-1.1 pp
SIGASIGA Technologies, Inc.LTM Mar 202665.4% -11.2 pp-22.0 pp
ESPREsperion Therapeutics, Inc.LTM Mar 202665.0% -0.3 pp+3.7 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 202663.5% -4.9 pp+2.1 pp
PRTAProthena Corporation plcLTM Mar 202646.8% -53.2 pp-38.2 pp
EBSEmergent BioSolutions Inc.LTM Mar 202644.4% +8.0 pp+4.9 pp
SNDLSNDL Inc.LTM Mar 202627.2% +0.6 pp+7.6 pp
CMPSCOMPASS Pathways plcFY2025— ——
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding EBS) 65.0%-4.9 pp-1.1 pp

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.